Media coverage about Allergan (NYSE:AGN) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Allergan earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.5780429210056 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s analysis:
- Botulinum Toxins Market Research Report 2018 – Allergan, Ipsen, Merz, Medytox Inc, US WorldMeds, LIBP (businessservices24.com)
- ALLERGAN, Lumenis, BTL INDUSTRIES, LTD., Merz Pharma And Other Are Dominating the Market For Global Medical … (newspharmaceuticals.com)
- Global Tissue Engineering Market 2018 by Players – Allergan, Integra Lifesciences, Osiris Therapeutics, Cryolife, ACell (theanalystfinancial.com)
- New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM … (globenewswire.com)
- Allergan to pay $3.5 mln over US claims of defective Lap-Bands (reuters.com)
A number of brokerages have issued reports on AGN. Cantor Fitzgerald set a $191.00 price target on Allergan and gave the stock a “hold” rating in a report on Thursday, April 12th. Vetr downgraded Allergan from a “buy” rating to a “hold” rating and set a $171.99 price target for the company. in a report on Tuesday. Stifel Nicolaus began coverage on Allergan in a report on Tuesday. They set a “hold” rating and a $192.00 price target for the company. Deutsche Bank reissued a “buy” rating on shares of Allergan in a report on Thursday, April 12th. Finally, Royal Bank of Canada set a $218.00 target price on Allergan and gave the company a “buy” rating in a report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $220.91.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The company had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same quarter in the prior year, the company posted $3.90 EPS. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. equities research analysts anticipate that Allergan will post 15.59 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date was Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is currently 17.61%.
In other news, insider William Meury sold 58,879 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brent L. Saunders acquired 3,300 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were purchased at an average price of $152.53 per share, with a total value of $503,349.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 8,095 shares of company stock worth $1,258,081. Corporate insiders own 0.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Allergan (AGN) Getting Somewhat Favorable Media Coverage, Accern Reports” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2018/04/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-allergan-agn-stock-price.html.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.